Discussion Question #1: From the outset, the research team was explicitly concerned about inequality in type 2 diabetes care and outcomes. Their aim was not just to improve to improve diabetes

treatment in general, but to do so for all. How can they best achieve this? Might Technology different users sometimes require different treatment protocols? Does the research team have a responsibility to single out users who are not receiving the full benefit of Charlie's interventions for special attention and/or treatment?